Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies
Author:
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),General Neuroscience
Link
http://link.springer.com/article/10.1007/s11910-017-0800-8/fulltext.html
Reference89 articles.
1. Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then Bergh F, Dose T, et al. Multiple sclerosis: comparison of copolymer-1 reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci U S A. 2000;97:7452–7.
2. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, TH2-polarized immune responses in patients with multiple sclerosis. J Clin Invest. 2000;105:967–76.
3. Haas J, Korporal M, Balint B, Fritzsching B, Schwarz A, Wildemann B. Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis. J Neuroimmunol. 2009;216(1-2):113–7. https://doi.org/10.1016/j.jneuroim.2009.06.011 .
4. Aharoni R, Eilam R, Stock A, Vainshtein A, Shezen E, Gal H, et al. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE. J Neuroimmunol. 2010;225(1-2):100–11. https://doi.org/10.1016/j.jneuroim.2010.04.022 .
5. Spadaro M, Montarolo F, Perga S, Martire S, Brescia F, Malucchi S, et al. Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10years in responder multiple sclerosis patients. Clin Immunol. 2017; https://doi.org/10.1016/j.clim.2017.06.006 .
Cited by 75 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Chronic disseminated histoplasmosis in a patient on fingolimod therapy: A case report and review of literature;Clinical Immunology Communications;2024-12
2. Effects of vaccination on COVID-19 infection symptoms in multiple sclerosis patients;eNeurologicalSci;2024-09
3. Cryptococcosis Associated With Biologic Therapy: A Narrative Review;Open Forum Infectious Diseases;2024-06-26
4. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS;JAMA Neurology;2024-05-01
5. Knowledge domain and trend of disease-modifying therapies for multiple sclerosis: A study based on CiteSpace;Heliyon;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3